Cargando…

Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy

The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Huan, Chen, Ze-Tan, Zhu, Xiao-Dong, Li, Ling, Qu, Song, Wei, Zhao, Su, Fang, Wei, Jing-Ni, Liang, Zhong-Guo, Mo, Qi-Yan, Wu, Jiang-Bo, Meng, Hui-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/
https://www.ncbi.nlm.nih.gov/pubmed/28968954
http://dx.doi.org/10.18632/oncotarget.16399
_version_ 1783265681023696896
author Lin, Huan
Chen, Ze-Tan
Zhu, Xiao-Dong
Li, Ling
Qu, Song
Wei, Zhao
Su, Fang
Wei, Jing-Ni
Liang, Zhong-Guo
Mo, Qi-Yan
Wu, Jiang-Bo
Meng, Hui-Ling
author_facet Lin, Huan
Chen, Ze-Tan
Zhu, Xiao-Dong
Li, Ling
Qu, Song
Wei, Zhao
Su, Fang
Wei, Jing-Ni
Liang, Zhong-Guo
Mo, Qi-Yan
Wu, Jiang-Bo
Meng, Hui-Ling
author_sort Lin, Huan
collection PubMed
description The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radioresistant NPC was significantly higher than that with radiosensitive NPC. In vitro, the CD166 positive rate in the CNE2 cell membrane was significantly lower than that in the CNE2R cell membrane. The magnetic-activated cell sorting technology was used to obtain CNE-2R-CD166(+) and CNE-2R-CD166(−) cell lines. Then radiosensitivity, cell proliferation, and apoptosis were assessed using colony formation assay, cell counting kit 8 assay (CCK-8), and flow cytometry, respectively. The radiation sensitivity ratio was 1.28, indicating that the CNE2R-CD166(−) cells had a stronger radiation sensitivity. The result of CCK-8 assay indicated that the survival fraction of CNE2R-CD166(+) cells was significantly higher than that of CNE2R-CD166(−) cells. The apoptotic rate of CNE2R-CD166(+) cells was significantly lower than that of CNE2R-CD166(−) cells. Our data demonstrate that the secreted protein CD166 may be can used as a biomarker for predicting the response of NPC to radiotherapy.
format Online
Article
Text
id pubmed-5609886
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56098862017-09-29 Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy Lin, Huan Chen, Ze-Tan Zhu, Xiao-Dong Li, Ling Qu, Song Wei, Zhao Su, Fang Wei, Jing-Ni Liang, Zhong-Guo Mo, Qi-Yan Wu, Jiang-Bo Meng, Hui-Ling Oncotarget Research Paper The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected by enzyme-linked immunosorbent assay. The secreted level of CD166 with radioresistant NPC was significantly higher than that with radiosensitive NPC. In vitro, the CD166 positive rate in the CNE2 cell membrane was significantly lower than that in the CNE2R cell membrane. The magnetic-activated cell sorting technology was used to obtain CNE-2R-CD166(+) and CNE-2R-CD166(−) cell lines. Then radiosensitivity, cell proliferation, and apoptosis were assessed using colony formation assay, cell counting kit 8 assay (CCK-8), and flow cytometry, respectively. The radiation sensitivity ratio was 1.28, indicating that the CNE2R-CD166(−) cells had a stronger radiation sensitivity. The result of CCK-8 assay indicated that the survival fraction of CNE2R-CD166(+) cells was significantly higher than that of CNE2R-CD166(−) cells. The apoptotic rate of CNE2R-CD166(+) cells was significantly lower than that of CNE2R-CD166(−) cells. Our data demonstrate that the secreted protein CD166 may be can used as a biomarker for predicting the response of NPC to radiotherapy. Impact Journals LLC 2017-03-21 /pmc/articles/PMC5609886/ /pubmed/28968954 http://dx.doi.org/10.18632/oncotarget.16399 Text en Copyright: © 2017 Lin et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Lin, Huan
Chen, Ze-Tan
Zhu, Xiao-Dong
Li, Ling
Qu, Song
Wei, Zhao
Su, Fang
Wei, Jing-Ni
Liang, Zhong-Guo
Mo, Qi-Yan
Wu, Jiang-Bo
Meng, Hui-Ling
Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title_full Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title_fullStr Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title_full_unstemmed Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title_short Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
title_sort serum cd166: a novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609886/
https://www.ncbi.nlm.nih.gov/pubmed/28968954
http://dx.doi.org/10.18632/oncotarget.16399
work_keys_str_mv AT linhuan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT chenzetan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT zhuxiaodong serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT liling serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT qusong serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT weizhao serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT sufang serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT weijingni serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT liangzhongguo serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT moqiyan serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT wujiangbo serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy
AT menghuiling serumcd166anovelbiomarkerforpredictingnasopharyngealcarcinomaresponsetoradiotherapy